Plasma-derived product · Kills target cells · developed by Replimune
Sturlimogene erparepvec is a genetically modified herpes simplex virus type 1 that replicates in and lyses tumor cells. It expresses GM-CSF and an antibody-like molecule against CTLA-4, which together promote a cytotoxic T-lymphocyte response against tumor cells. It is studied in hepatocellular carcinoma, biliary tract cancer, uveal melanoma, cutaneous melanoma and high-risk oral precancerous disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06581406 | Phase 2/3 | Metastatic Uveal Melanoma | Recruiting | REPL |
| NCT07862530 | Phase 2 | MelanomaCutaneous Melanoma Resectable, Melanoma | Not yet recruiting | REPL |
| NCT06623110 | Phase 2 | High-Risk Oral Precancerous Disease | Recruiting | REPL |
| NCT05733598 | Phase 2 | Hepatocellular Carcinoma | Recruiting | REPL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Biliary Tract CancerHepatocellular CarcinomaHigh-Risk Oral Precancerous DiseaseMelanomaCutaneous Melanoma Resectable, MelanomaMetastatic Uveal Melanoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the REPL page.
See REPL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REPL catalysts and pipeline →